have signed a licensing agreement for cardiovascular and diabetes products in Germany. UCB has extended commercial rights for the German market to the cardiovascular medication Provas beyond 2011 and has licensed in commercial rights for two line extensions: Dafiro and Dafiro HCT. In addition, UCB will co-commercialize two new oral anti-diabetics Jalra and Icandra.
